<li>acebutolol<p>acebutolol and verapamil both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>aldesleukin<p>aldesleukin increases effects of verapamil by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.</p></li><li>alfentanil<p>verapamil will increase the level or effect of alfentanil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. The risk of significant hypotension and/or bradycardia during therapy with alfentanil may be increased in patients receiving calcium-channel blockers.</p></li><li>alfuzosin<p>alfuzosin and verapamil both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>aliskiren<p>verapamil will increase the level or effect of aliskiren by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>verapamil will increase the level or effect of aliskiren by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>alitretinoin<p>verapamil will increase the level or effect of alitretinoin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>almotriptan<p>verapamil will increase the level or effect of almotriptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>alprazolam<p>verapamil will increase the level or effect of alprazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>amifostine<p>amifostine increases effects of verapamil by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.</p></li><li>amikacin<p>verapamil will increase the level or effect of amikacin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>amiodarone<p>verapamil will increase the level or effect of amiodarone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>amiodarone will increase the level or effect of verapamil by  basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor.<span><br><br></span>amiodarone, verapamil. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of cardiotoxicity with bradycardia.</p></li><li>amitriptyline<p>verapamil will increase the level or effect of amitriptyline by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. The frequency and severity of amitriptyline adverse effects (sedation, anticholinergic effects and orthostatic hypotension) may be increased. Cardiac dysrhythmic effects may be additive. </p></li><li>amlodipine<p>amlodipine and verapamil both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>amobarbital<p>amobarbital will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>amphetamine<p>amphetamine decreases effects of verapamil by pharmacodynamic antagonism. Use Caution/Monitor.<span><br><br></span>amphetamine increases toxicity of verapamil by serotonin levels. Use Caution/Monitor. Closely monitor for signs and symptoms of serotonin syndrome (eg, agitation, tremor, tachycardia).</p></li><li>apixaban<p>verapamil will increase the level or effect of apixaban by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Verapamil also inhibits P-gp activity, which can further increase apixaban serum levels; since both pathways of apixaban elimination are affected, patients with renal impairment receiving apixaban with drugs that are combined P-gp and moderate CYP3A4 inhibitors may increase exposure compared to patients with normal renal function; monitor for bleeding.</p></li><li>aprepitant<p>aprepitant will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>aripiprazole<p>verapamil will increase the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>armodafinil<p>armodafinil will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>artemether/lumefantrine<p>verapamil will increase the level or effect of artemether/lumefantrine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>asenapine<p>asenapine and verapamil both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>atazanavir<p>atazanavir will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>verapamil will increase the level or effect of atazanavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Caution advised, may increase risk of AV block</p></li><li>atenolol<p>atenolol and verapamil both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>atorvastatin<p>verapamil will increase the level or effect of atorvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>verapamil will increase the level or effect of atorvastatin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>avanafil<p>verapamil will increase the level or effect of avanafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. CYP3A4 inhibitors may reduce avanafil clearance increasing systemic exposure to avanafil; increased levels may result in increased associated adverse events; the maximum recommended dose of STENDRA is 50 mg, not to exceed once every 24 hours for patients taking concomitant moderate CYP3A4 inhibitors </p></li><li>azithromycin<p>verapamil will increase the level or effect of azithromycin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>bazedoxifene/conjugated estrogens<p>verapamil will increase the level or effect of bazedoxifene/conjugated estrogens by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>verapamil will increase the level or effect of bazedoxifene/conjugated estrogens by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>betaxolol<p>betaxolol and verapamil both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>bisoprolol<p>bisoprolol and verapamil both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>boceprevir<p>boceprevir increases levels of verapamil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>bortezomib<p>verapamil will increase the level or effect of bortezomib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>bosentan<p>bosentan will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>bosutinib<p>bosutinib increases levels of verapamil by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>brexpiprazole<p>verapamil will increase the level or effect of brexpiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Administer a quarter of brexpiprazole dose if coadministered with a moderate CYP3A4 inhibitor PLUS a strong/moderate CYP2D6 inhibitor.</p></li><li>budesonide<p>verapamil will increase the level or effect of budesonide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>budesonide will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>verapamil will increase the level or effect of budesonide by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>buprenorphine subdermal implant<p>verapamil will increase the level or effect of buprenorphine subdermal implant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Monitor patients already on buprenorphine subdermal implant who require newly-initiated treatment with CYP3A4 inhibitors for signs and symptoms of overmedication. If the dose of the concomitant CYP3A4 inhibitor cannot be reduced or discontinued, implant removal may be necessary and the patient should then be treated with a buprenorphine dosage form that permits dose adjustments. If a CYP3A4 inhibitor is discontinued in a patient who has been stabilized on buprenorphine, monitor the patient for withdrawal.</p></li><li>buspirone<p>verapamil will increase the level or effect of buspirone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Consider lower buspirone doses.</p></li><li>butabarbital<p>butabarbital will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>butalbital<p>butalbital will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>cabazitaxel<p>verapamil will increase the level or effect of cabazitaxel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Caution should be exercised with concomitant use of moderate CYP3A4 inhibitors.</p></li><li>cabozantinib<p>verapamil will increase the level or effect of cabozantinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>calcium acetate<p>calcium acetate decreases effects of verapamil by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>calcium carbonate<p>calcium carbonate decreases effects of verapamil by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>calcium chloride<p>calcium chloride decreases effects of verapamil by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>calcium citrate<p>calcium citrate decreases effects of verapamil by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>calcium gluconate<p>calcium gluconate decreases effects of verapamil by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>carbamazepine<p>verapamil will increase the level or effect of carbamazepine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor plasma levels when used concomitantly</p></li><li>carbidopa<p>carbidopa increases effects of verapamil by pharmacodynamic synergism. Use Caution/Monitor. Therapy with carbidopa, given with or without levodopa or carbidopa-levodopa combination products, is started, dosage adjustment of the antihypertensive drug may be required.</p></li><li>carvedilol<p>carvedilol and verapamil both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>celiprolol<p>celiprolol and verapamil both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>ceritinib<p>verapamil increases levels of ceritinib by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>cilostazol<p>verapamil will increase the level or effect of cilostazol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Consider decreasing the cilostazol dose to 50 mg twice a day.</p></li><li>cimetidine<p>cimetidine will increase the level or effect of verapamil by  basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>cinacalcet<p>verapamil will increase the level or effect of cinacalcet by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>clarithromycin<p>clarithromycin will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Increased effect of calcium channel blockers may lead to hypotension, edema, decreased HR, and acute kidney injury due to reduced renal blood flow</p></li><li>clevidipine<p>clevidipine and verapamil both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>clobetasone<p>verapamil will increase the level or effect of clobetasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>clobetasone will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>verapamil will increase the level or effect of clobetasone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>clomipramine<p>verapamil will increase the level or effect of clomipramine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.</p></li><li>clonidine<p>clonidine, verapamil.
Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil. Monitor heart rate in patients receiving concomitant verapamil and clonidine.<span><br><br></span>verapamil, clonidine.
Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil. Monitor heart rate in patients receiving concomitant verapamil and clonidine.</p></li><li>clopidogrel<p>verapamil will decrease the level or effect of clopidogrel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Inhibition of CYP3A4 will reduce clopidogrel bioactivation</p></li><li>clozapine<p>verapamil will increase the level or effect of clozapine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.<span><br><br></span>verapamil will increase the level or effect of clozapine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>cobicistat<p>cobicistat will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>colchicine<p>verapamil will increase the level or effect of colchicine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Colchicine toxicity may occur. Colchicine dosing adjustment may be required for patients also receiving verapamil. <span><br><br></span>verapamil will increase the level or effect of colchicine by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Colchicine toxicity may occur. Colchicine dosing adjustment may be required for patients also receiving verapamil. </p></li><li>conivaptan<p>conivaptan will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>conjugated estrogens<p>verapamil will increase the level or effect of conjugated estrogens by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>verapamil will increase the level or effect of conjugated estrogens by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>conjugated estrogens, vaginal<p>verapamil will increase the level or effect of conjugated estrogens, vaginal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>verapamil will increase the level or effect of conjugated estrogens, vaginal by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>cortisone<p>verapamil will increase the level or effect of cortisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>cortisone will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>verapamil will increase the level or effect of cortisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>crizotinib<p>crizotinib increases levels of verapamil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Dose reduction may be needed for coadministered drugs that are predominantly metabolized by CYP3A.<span><br><br></span>crizotinib increases levels of verapamil by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.<span><br><br></span>verapamil increases levels of crizotinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Caution should be exercised with concomitant use of moderate CYP3A inhibitors. .</p></li><li>crofelemer<p>crofelemer increases levels of verapamil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Crofelemer has the potential to inhibit CYP3A4 at concentrations expected in the gut; unlikely to inhibit systemically because minimally absorbed.</p></li><li>cyclosporine<p>verapamil will increase the level or effect of cyclosporine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.<span><br><br></span>cyclosporine will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>verapamil will increase the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>verapamil will increase the level or effect of cyclosporine by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>dabigatran<p>verapamil will increase the level or effect of dabigatran by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Atrial fibrillation: Avoid coadministering dabigatran with P-gp inhibitors if CrCl &lt;30 mL/min.  DVT/PE treatment: Avoid coadministering dabigatran with P-gp inhibitors if CrCl &lt;50 mL/min</p></li><li>dabrafenib<p>dabrafenib will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.</p></li><li>daclatasvir<p>verapamil will increase the level or effect of daclatasvir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Caution with moderate CYP3A4 inhibitors.<span><br><br></span>daclatasvir will increase the level or effect of verapamil by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>darifenacin<p>darifenacin will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>verapamil will increase the level or effect of darifenacin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>darunavir<p>darunavir will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>dasatinib<p>dasatinib will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>daunorubicin<p>verapamil will increase the level or effect of daunorubicin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>daunorubicin liposomal<p>verapamil will increase the level or effect of daunorubicin liposomal by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>deferasirox<p>deferasirox will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>deflazacort<p>verapamil will increase the level or effect of deflazacort by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Decrease deflazacort dose to one-third of the recommended dose if coadministered with moderate or strong CYP3A4 inhibitors.<span><br><br></span>verapamil will increase the level or effect of deflazacort by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>delavirdine<p>delavirdine will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>desipramine<p>verapamil will increase the level or effect of desipramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>dexamethasone<p>verapamil will increase the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>dexamethasone will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>verapamil will increase the level or effect of dexamethasone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>dhea, herbal<p>dhea, herbal will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>diazepam<p>verapamil will increase the level or effect of diazepam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>dienogest/estradiol valerate<p>verapamil will increase the level or effect of dienogest/estradiol valerate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor for potential adverse effects such as nausea, irregular uterine bleeding, breast tenderness and headache.</p></li><li>digoxin<p>verapamil will increase the level or effect of digoxin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Toxicity characterized by gastrointestinal and neuropsychiatric symptoms, and cardiac arrhythmias may result.<span><br><br></span>digoxin will increase the level or effect of verapamil by  basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>diltiazem<p>diltiazem will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>verapamil will increase the level or effect of diltiazem by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. These agents have additive hypotensive effects that may be beneficial however, it is important to monitor patients carefully.<span><br><br></span>diltiazem and verapamil both increase  anti-hypertensive channel blocking. Use Caution/Monitor. Antihypertensives may enhance the hypotensive effects of other antihypertensive agents when used together.</p></li><li>disopyramide<p>verapamil will increase the level or effect of disopyramide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Avoid disopyramide administration within 48 hours before or 24 hours after verapamil administration.</p></li><li>docetaxel<p>verapamil will increase the level or effect of docetaxel by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>dofetilide<p>dofetilide will increase the level or effect of verapamil by  basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>doxazosin<p>doxazosin and verapamil both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>doxorubicin<p>verapamil will increase the level or effect of doxorubicin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>verapamil increases levels of doxorubicin by decreasing metabolism. Use Caution/Monitor. Coadministration of doxorubicin and calcium channel blockers may increase the risk of doxorubicin cardiotoxicity. .</p></li><li>doxorubicin liposomal<p>verapamil will increase the level or effect of doxorubicin liposomal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>verapamil increases toxicity of doxorubicin liposomal by decreasing metabolism. Use Caution/Monitor. Coadministration of doxorubicin and calcium channel blockers may increase the risk of doxorubicin cardiotoxicity. .</p></li><li>dronedarone<p>dronedarone will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>dyphylline<p>verapamil will increase the level or effect of dyphylline by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.<span><br><br></span>verapamil will increase the level or effect of dyphylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>efavirenz<p>efavirenz will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>eletriptan<p>verapamil will increase the level or effect of eletriptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>eliglustat<p>eliglustat increases levels of verapamil by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Monitor therapeutic drug concentrations, as indicated, or consider reducing the dosage of the P-gp substrate and titrate to clinical effect.</p></li><li>elvitegravir/cobicistat/emtricitabine/tenofovir df<p>elvitegravir/cobicistat/emtricitabine/tenofovir df increases levels of verapamil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP3A4 inhibitor; contraindicated with CYP3A4 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events.</p></li><li>eplerenone<p>verapamil will increase the level or effect of eplerenone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Plasma concentrations and pharmacologic or toxic effects of eplerenone may be increased by verapamil.</p></li><li>erlotinib<p>verapamil will increase the level or effect of erlotinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>eslicarbazepine acetate<p>eslicarbazepine acetate will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>verapamil decreases levels of eslicarbazepine acetate by increasing metabolism. Modify Therapy/Monitor Closely.</p></li><li>esmolol<p>esmolol and verapamil both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>estradiol<p>verapamil will increase the level or effect of estradiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>verapamil will increase the level or effect of estradiol by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>estrogens conjugated synthetic<p>verapamil will increase the level or effect of estrogens conjugated synthetic by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>verapamil will increase the level or effect of estrogens conjugated synthetic by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>estrogens esterified<p>verapamil will increase the level or effect of estrogens esterified by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>estropipate<p>verapamil will increase the level or effect of estropipate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>verapamil will increase the level or effect of estropipate by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>ethanol<p>verapamil increases levels of ethanol by decreasing metabolism. Use Caution/Monitor.</p></li><li>ethotoin<p>ethotoin will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>etonogestrel<p>verapamil will increase the level or effect of etonogestrel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>etoposide<p>verapamil will increase the level or effect of etoposide by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>etravirine<p>verapamil will increase the level or effect of etravirine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>eucalyptus<p>eucalyptus will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>everolimus<p>verapamil will increase the level or effect of everolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Concomitant use of a moderate 3A4 inhibitor such as verapamil may significantly increase the plasma concentrations of everolimus following oral administration.<span><br><br></span>verapamil will increase the level or effect of everolimus by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Everolimus prescribing information lists indication-specific dosing recommendations.<span><br><br></span>everolimus will increase the level or effect of verapamil by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Everolimus prescribing information lists indication-specific dosing recommendations.</p></li><li>felodipine<p>verapamil will increase the level or effect of felodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>felodipine and verapamil both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>fesoterodine<p>verapamil will increase the level or effect of fesoterodine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>fluconazole<p>fluconazole will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>fludrocortisone<p>verapamil will increase the level or effect of fludrocortisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>fludrocortisone will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>verapamil will increase the level or effect of fludrocortisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>fluvoxamine<p>fluvoxamine will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>fosamprenavir<p>fosamprenavir will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>fosphenytoin<p>fosphenytoin will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>gentamicin<p>verapamil will increase the level or effect of gentamicin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>grapefruit<p>grapefruit will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>green tea<p>verapamil increases levels of green tea by decreasing elimination. Use Caution/Monitor. (Caffeine).  Verapamil reduces clearance of caffeine and increases serum caffeine concentrations, presumably via inhibition of hepatic metabolism. May advise patients to limit or minimize the intake of caffeinated products to minimize caffeine-related side effects.</p></li><li>griseofulvin<p>griseofulvin will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>guanfacine<p>verapamil will increase the level or effect of guanfacine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Strong or moderate CYP3A4 inhibitors significantly increase guanfacine plasma concentrations. FDA-approved labeling for extended-release (ER) guanfacine recommends that, if coadministered, the guanfacine dosage should be decreased to half of the recommended dose. Specific recommendations for immediate-release (IR) guanfacine are not available. </p></li><li>hawthorn<p>hawthorn increases effects of verapamil by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>hexobarbital<p>hexobarbital will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>hydrocortisone<p>verapamil will increase the level or effect of hydrocortisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>hydrocortisone will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>verapamil will increase the level or effect of hydrocortisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>hydroxyprogesterone caproate<p>verapamil will increase the level or effect of hydroxyprogesterone caproate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>iloperidone<p>verapamil will increase the level or effect of iloperidone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>iloperidone increases levels of verapamil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Iloperidone is a time-dependent CYP3A inhibitor and may lead to increased plasma levels of drugs predominantly eliminated by CYP3A4.</p></li><li>imatinib<p>verapamil will increase the level or effect of imatinib by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>imipramine<p>verapamil will increase the level or effect of imipramine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.<span><br><br></span>verapamil will increase the level or effect of imipramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. TCA level may be increased.</p></li><li>indacaterol, inhaled<p>verapamil increases levels of indacaterol, inhaled by Other (see comment). Use Caution/Monitor. 
Comment: Data suggests that systemic clearance is influenced by modulation of both P-gp and CYP3A4 activities. No dose adjustment is warranted at the 75 mcg dose.</p></li><li>indinavir<p>indinavir will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>verapamil will increase the level or effect of indinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>verapamil will increase the level or effect of indinavir by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>irinotecan<p>verapamil will increase the level or effect of irinotecan by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>irinotecan liposomal<p>verapamil will increase the level or effect of irinotecan liposomal by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>isoniazid<p>isoniazid will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>isradipine<p>isradipine and verapamil both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>itraconazole<p>verapamil will increase the level or effect of itraconazole by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>ivabradine<p>verapamil, ivabradine.
Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Most patients receiving ivabradine will also be treated with a beta-blocker. The risk of bradycardia increases with  coadministration of drugs that slow heart rate (eg, digoxin, amiodarone, beta-blockers). Monitor heart rate in patients taking ivabradine with other negative chronotropes.</p></li><li>ivermectin<p>verapamil will increase the level or effect of ivermectin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>ixabepilone<p>verapamil will increase the level or effect of ixabepilone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>kanamycin<p>verapamil will increase the level or effect of kanamycin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>labetalol<p>labetalol and verapamil both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>lacidipine<p>verapamil will increase the level or effect of lacidipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>lacidipine and verapamil both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>lapatinib<p>lapatinib will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>verapamil will increase the level or effect of lapatinib by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>lercanidipine<p>verapamil will increase the level or effect of lercanidipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>lercanidipine and verapamil both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>levobupivacaine<p>verapamil will increase the level or effect of levobupivacaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.<span><br><br></span>verapamil will increase the level or effect of levobupivacaine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>levodopa<p>levodopa increases effects of verapamil by pharmacodynamic synergism. Use Caution/Monitor. Consider decreasing dosage of antihypertensive agent.</p></li><li>lidocaine<p>verapamil will increase the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.</p></li><li>lomitapide<p>lomitapide increases levels of verapamil by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Consider reducing dose when used concomitantly with lomitapide.</p></li><li>loperamide<p>verapamil will increase the level or effect of loperamide by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>lopinavir<p>verapamil will increase the level or effect of lopinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>loratadine<p>verapamil will increase the level or effect of loratadine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>lovastatin<p>verapamil will increase the level or effect of lovastatin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Avoid concomitant use of verapamil and lovastatin if possible. If used together, use lower doses of lovastatin and monitor for lovastatin toxicity (myositis, rhabdomyolysis).</p></li><li>lumefantrine<p>verapamil will increase the level or effect of lumefantrine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>lurasidone<p>verapamil increases levels of lurasidone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Manufacturer recommends decreasing starting dose of lurasidone to 20 mg/day and maximum daily dose of lurasidone 80 mg when coadministered with moderate CYP3A4 inhibitors. Concurrent use may increase risk of lurasidone-related adverse reactions.<span><br><br></span>lurasidone increases effects of verapamil by Other (see comment). Use Caution/Monitor. 
Comment: Potential  for increased risk of hypotension with concurrent use. Monitor blood pressure and adjust  dose of  antihypertensive agent as needed.</p></li><li>maraviroc<p>verapamil will increase the level or effect of maraviroc by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>verapamil will increase the level or effect of maraviroc by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>marijuana<p>marijuana will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>mefloquine<p>mefloquine increases levels of verapamil by decreasing metabolism. Use Caution/Monitor. Risk of arrhythmia.<span><br><br></span>verapamil will increase the level or effect of mefloquine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>mephobarbital<p>mephobarbital will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>mestranol<p>verapamil will increase the level or effect of mestranol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>verapamil will increase the level or effect of mestranol by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>methadone<p>verapamil will increase the level or effect of methadone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>methylprednisolone<p>verapamil will increase the level or effect of methylprednisolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>methylprednisolone will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>verapamil will increase the level or effect of methylprednisolone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>metoprolol<p>metoprolol and verapamil both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>metronidazole<p>metronidazole will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>mexiletine<p>verapamil will increase the level or effect of mexiletine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.</p></li><li>mibefradil<p>mibefradil will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>miconazole vaginal<p>miconazole vaginal will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>midazolam<p>verapamil will increase the level or effect of midazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>mifepristone<p>verapamil will increase the level or effect of mifepristone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>mipomersen<p>mipomersen, verapamil.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: Both drugs have potential to increase hepatic enzymes; monitor LFTs.</p></li><li>mitotane<p>mitotane decreases levels of verapamil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Mitotane is a strong inducer of cytochrome P-4503A4; monitor when coadministered with CYP3A4 substrates for possible dosage adjustments.</p></li><li>modafinil<p>modafinil will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>moxisylyte<p>moxisylyte and verapamil both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>mycophenolate<p>verapamil will increase the level or effect of mycophenolate by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>nadolol<p>nadolol and verapamil both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>nafcillin<p>nafcillin will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>nafcillin decreases levels of verapamil by increasing metabolism. Use Caution/Monitor.</p></li><li>nebivolol<p>nebivolol and verapamil both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>nelfinavir<p>nelfinavir will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>verapamil will increase the level or effect of nelfinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>verapamil will increase the level or effect of nelfinavir by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>neomycin po<p>verapamil will increase the level or effect of neomycin po by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>netilmicin<p>verapamil will increase the level or effect of netilmicin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>nevirapine<p>nevirapine will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>nicardipine<p>verapamil will increase the level or effect of nicardipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>nicardipine and verapamil both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>nifedipine<p>nifedipine will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>nifedipine and verapamil both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>nilotinib<p>nilotinib will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>verapamil will increase the level or effect of nilotinib by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>nintedanib<p>verapamil increases levels of nintedanib by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. If nintedanib adverse effects occur, management may require interruption, dose reduction, or discontinuation of therapy .</p></li><li>nisoldipine<p>verapamil will increase the level or effect of nisoldipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>nisoldipine and verapamil both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>nitroglycerin rectal<p>nitroglycerin rectal, verapamil.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Marked orthostatic hypotension has been reported when calcium channel blockers and organic nitrates were used concomitantly. Observe for possible additive hypotensive effects during concomitant use. .</p></li><li>nitroglycerin sublingual<p>verapamil, nitroglycerin sublingual.
Either increases toxicity of the other by additive vasodilation. Modify Therapy/Monitor Closely. Marked orthostatic hypotension reported with concomitant use.</p></li><li>nitroprusside sodium<p>verapamil increases effects of nitroprusside sodium by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>nortriptyline<p>verapamil will increase the level or effect of nortriptyline by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>olanzapine<p>verapamil will increase the level or effect of olanzapine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.</p></li><li>ombitasvir/paritaprevir/ritonavir<p>ombitasvir/paritaprevir/ritonavir will increase the level or effect of verapamil by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Paritaprevir and ritonavir inhibit P-gp. Caution if coadministered with P-gp substrates.</p></li><li>ombitasvir/paritaprevir/ritonavir &amp; dasabuvir<p>ombitasvir/paritaprevir/ritonavir &amp; dasabuvir will increase the level or effect of verapamil by  altering metabolism. Modify Therapy/Monitor Closely. Decrease dose of calcium channel blocker; clinical monitoring of patients is recommended for edema and/or signs and symptoms of hypotension. if such events occur, consider further dose reduction of  calcium channel blocker or switching to alternative to calcium channel blocker m channel blocker dose if necessary</p></li><li>oxcarbazepine<p>oxcarbazepine will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>oxiconazole<p>oxiconazole will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>paclitaxel<p>verapamil will increase the level or effect of paclitaxel by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>paclitaxel protein bound<p>verapamil will increase the level or effect of paclitaxel protein bound by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>palbociclib<p>verapamil will increase the level or effect of palbociclib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>paliperidone<p>verapamil will increase the level or effect of paliperidone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>paromomycin<p>verapamil will increase the level or effect of paromomycin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>penbutolol<p>penbutolol and verapamil both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>pentobarbital<p>pentobarbital will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>phenobarbital<p>phenobarbital will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>phenoxybenzamine<p>phenoxybenzamine and verapamil both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>phentolamine<p>phentolamine and verapamil both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>phenytoin<p>phenytoin will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>pindolol<p>pindolol and verapamil both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>ponatinib<p>ponatinib increases levels of verapamil by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>posaconazole<p>posaconazole will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>verapamil will increase the level or effect of posaconazole by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>prazosin<p>prazosin and verapamil both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>prednisolone<p>verapamil will increase the level or effect of prednisolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>prednisolone will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>verapamil will increase the level or effect of prednisolone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>prednisone<p>verapamil will increase the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>prednisone will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>verapamil will increase the level or effect of prednisone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>primidone<p>primidone will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>procainamide<p>procainamide will increase the level or effect of verapamil by  basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>propranolol<p>propranolol and verapamil both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>quetiapine<p>verapamil will increase the level or effect of quetiapine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>quinidine<p>verapamil will increase the level or effect of quinidine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>quinidine will increase the level or effect of verapamil by  basic (cationic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>quinupristin/dalfopristin<p>quinupristin/dalfopristin will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>repaglinide<p>verapamil will increase the level or effect of repaglinide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>rifapentine<p>rifapentine will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>rifaximin<p>verapamil increases levels of rifaximin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>rimonabant<p>verapamil will increase the level or effect of rimonabant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>risperidone<p>verapamil will increase the level or effect of risperidone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>ritonavir<p>ritonavir will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>verapamil will increase the level or effect of ritonavir by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>rivaroxaban<p>verapamil increases levels of rivaroxaban by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Verapamil also inhibits P-gp activity, which can further increase rivaroxaban serum levels; since both pathways of rivaroxaban elimination are affected, patients with renal impairment receiving rivaroxaban with drugs that are combined P-gp and moderate CYP3A4 inhibitors may increase exposure compared to patients with normal renal function; monitor for bleeding.</p></li><li>romidepsin<p>verapamil will increase the level or effect of romidepsin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>verapamil will increase the level or effect of romidepsin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>rufinamide<p>rufinamide will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>ruxolitinib<p>verapamil will increase the level or effect of ruxolitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>saquinavir<p>verapamil will increase the level or effect of saquinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>verapamil will increase the level or effect of saquinavir by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>secobarbital<p>secobarbital will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>sevelamer<p>sevelamer decreases levels of verapamil by increasing elimination. Use Caution/Monitor.</p></li><li>sildenafil<p>verapamil will increase the level or effect of sildenafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>silodosin<p>verapamil will increase the level or effect of silodosin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.<span><br><br></span>silodosin and verapamil both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>simeprevir<p>simeprevir increases levels of verapamil by decreasing metabolism. Modify Therapy/Monitor Closely. May result in increased plasma concentrations of calcium channel blockers due to intestinal CYP3A4 and/or P-gp inhibition by simeprevir.</p></li><li>sirolimus<p>verapamil will increase the level or effect of sirolimus by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>sitaxentan<p>sitaxentan will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>solifenacin<p>verapamil will increase the level or effect of solifenacin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>sonidegib<p>verapamil will increase the level or effect of sonidegib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Avoid coadministration of sonidegib with moderate CYP3A4 inhibitors. If a moderate CYP3A inhibitor must be used, administer the moderate CYP3A inhibitor for &lt;14 days and monitor closely for adverse reactions, particularly musculoskeletal adverse reactions.</p></li><li>sotalol<p>sotalol and verapamil both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>streptomycin<p>verapamil will increase the level or effect of streptomycin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>sufentanil<p>verapamil will increase the level or effect of sufentanil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. There may be an increased incidence of bradycardia and hypotension during induction with sufentanil in patients receiving calcium channel blockers such as verapamil.</p></li><li>sunitinib<p>verapamil will increase the level or effect of sunitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>suvorexant<p>verapamil will increase the level or effect of suvorexant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Decrease suvorexant starting dose to 5 mg HS if coadministered with moderate CYP3A4 inhibitors</p></li><li>tacrolimus<p>verapamil will increase the level or effect of tacrolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>verapamil will increase the level or effect of tacrolimus by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>tadalafil<p>verapamil will increase the level or effect of tadalafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Risk of hypotension.</p></li><li>tamoxifen<p>verapamil will increase the level or effect of tamoxifen by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. CYP3A4 inhibition decreases metabolism of tamoxifen to N-desmethyl tamoxifen (active metabolite with similar biologic activity)</p></li><li>tapentadol<p>verapamil and tapentadol both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>telaprevir<p>telaprevir increases levels of verapamil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Concentrations of calcium channel blockers may be increased when telaprevir is co-administered. Caution is warranted and clinical monitoring of patients is recommended.</p></li><li>telithromycin<p>telithromycin will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>temsirolimus<p>verapamil will increase the level or effect of temsirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>teniposide<p>verapamil will increase the level or effect of teniposide by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>tenofovir df<p>tenofovir df increases levels of verapamil by decreasing renal clearance. Use Caution/Monitor. Potential for increased toxicity. .</p></li><li>terazosin<p>terazosin and verapamil both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li><li>theophylline<p>verapamil will increase the level or effect of theophylline by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.<span><br><br></span>verapamil will increase the level or effect of theophylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>timolol<p>timolol and verapamil both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.</p></li><li>tipranavir<p>verapamil will increase the level or effect of tipranavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>tipranavir, verapamil. Other (see comment). Use Caution/Monitor. 
Comment: Verapamil levels may incr or decr, due to contradictory effects of tipranavir on hepatic CYP3A4 and P glycoprotein.</p></li><li>tobramycin<p>verapamil will increase the level or effect of tobramycin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>tofacitinib<p>verapamil increases levels of tofacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No specific dose adjustment recommended when tofacitinib coadministered with moderate CYP3A4 inhibitors; decrease tofacitinib dose if coadministered with both moderate CYP3A4 and potent CYP2C19 inhibitors .</p></li><li>tolterodine<p>verapamil will increase the level or effect of tolterodine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>tolvaptan<p>verapamil will increase the level or effect of tolvaptan by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Coadministration of moderate CYP 3A inhibitors, such as Verapamil with Tolvaptan should be avoided.</p></li><li>topiramate<p>topiramate will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>trabectedin<p>verapamil will increase the level or effect of trabectedin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>trazodone<p>verapamil will increase the level or effect of trazodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>triamcinolone<p>verapamil will increase the level or effect of triamcinolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>triamcinolone will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>verapamil will increase the level or effect of triamcinolone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>triazolam<p>verapamil will increase the level or effect of triazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>trimagnesium citrate anhydrous<p>trimagnesium citrate anhydrous, verapamil.
Either increases effects of the other by sedation. Use Caution/Monitor. Possible additive effect of magnesium and calcium channel blockers on reduction of ionic calcium may increase risk of hypotension or muscle weakness.</p></li><li>troglitazone<p>troglitazone will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>troleandomycin<p>troleandomycin will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>vardenafil<p>verapamil will increase the level or effect of vardenafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>vemurafenib<p>verapamil increases levels of vemurafenib by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.<span><br><br></span>vemurafenib increases levels of verapamil by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>vinblastine<p>verapamil will increase the level or effect of vinblastine by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>vincristine<p>verapamil will increase the level or effect of vincristine by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>vincristine liposomal<p>verapamil will increase the level or effect of vincristine liposomal by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>vismodegib<p>verapamil will increase the level or effect of vismodegib by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Vismodegib is a substrate of efflux transporter P-glycoprotein (P-gp); coadministration with P-gp inhibitors increase vismodegib systemic exposure</p></li><li>voriconazole<p>voriconazole will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Combo may increase risk of hypotension, bradycardia, AV block.<span><br><br></span>voriconazole increases levels of verapamil by decreasing metabolism. Use Caution/Monitor.</p></li><li>warfarin<p>verapamil will increase the level or effect of warfarin by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.<span><br><br></span>verapamil will increase the level or effect of warfarin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>xipamide<p>xipamide increases effects of verapamil by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>zafirlukast<p>zafirlukast will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>zotepine<p>zotepine and verapamil both increase  anti-hypertensive channel blocking. Use Caution/Monitor.</p></li>